PRNewsWire
01 Jun 2026, 00:15 UTC · 2h ago
Source · https://www.prnewswire.com/news-releases/asco-2026--cstone-presents-updated-clinical-data-for-cs2009-pd-1vegfctla-4-trispecific-antibody-reinforcing-triple-target-synergy-and-delivering-strong-proof-of-concept-302786438.html
Read source
Story key points
5 claims · impact-rated
CStone Pharmaceuticals plans to initiate the first Phase III global multi-regional registrational trial (MRCT) for CS2009 by the end of 2026. — Transitioning to Phase III registrational trials is the most critical milestone for drug commercialization and valuation.
+0.80CS2009 monotherapy achieved an 81.3% objective response rate (ORR) and a 100% disease control rate (DCR) in first-line NSCLC patients with high PD-L1 expression. — High efficacy in a primary oncology indication provides strong proof-of-concept and increases the probability of regulatory success.
+0.70CS2009 demonstrated activity in 'cold tumors,' including a 66.7% ORR when combined with XELOX in first-line metastatic colorectal cancer. — Ability to treat immunotherapy-refractory tumors expands the addressable market and competitive advantage of the asset.
+0.50Continue reading
6 related stories
Search tags
Updated Phase I safety data confirmed a well-tolerated profile with no excessive toxicities typically associated with CTLA-4/PD-(L)1 combinations. — Reducing the toxicity associated with triple-targeting antibodies removes a major risk barrier for clinical adoption.
+0.40CStone has obtained U.S. Investigational New Drug (IND) clearance for the ongoing global Phase I/II trial of CS2009. — IND clearance is a necessary regulatory hurdle to enter the lucrative U.S. market.
+0.30Ticker attribution
Model heads
The company presented positive Phase I/II clinical data for its core asset CS2009, showing strong efficacy and a favorable safety profile.
No ticker relationship head found.
Impact vectors
4 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
PRNewsWire
1d ago
